274 related articles for article (PubMed ID: 27923595)
1. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
[TBL] [Abstract][Full Text] [Related]
3. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma
Shan NL; Minden A; Furmanski P; Bak MJ; Cai L; Wernyj R; Sargsyan D; Cheng D; Wu R; Kuo HD; Li SN; Fang M; Maehr H; Kong AN; Suh N
Cancer Prev Res (Phila); 2020 Aug; 13(8):673-686. PubMed ID: 32467291
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
6. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer.
So JY; Lee HJ; Smolarek AK; Paul S; Wang CX; Maehr H; Uskokovic M; Zheng X; Conney AH; Cai L; Liu F; Suh N
Mol Pharmacol; 2011 Mar; 79(3):360-7. PubMed ID: 21115634
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer.
So JY; Smolarek AK; Salerno DM; Maehr H; Uskokovic M; Liu F; Suh N
PLoS One; 2013; 8(1):e54020. PubMed ID: 23326564
[TBL] [Abstract][Full Text] [Related]
8. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
So JY; Lin JJ; Wahler J; Liby KT; Sporn MB; Suh N
PLoS One; 2014; 9(9):e107616. PubMed ID: 25229616
[TBL] [Abstract][Full Text] [Related]
9. Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)
Narvaez CJ; Bak MJ; Salman N; Welsh J
J Steroid Biochem Mol Biol; 2023 Jul; 231():106307. PubMed ID: 37030416
[TBL] [Abstract][Full Text] [Related]
10. Structural analysis and biological activities of BXL0124, a gemini analog of vitamin D.
Belorusova AY; Suh N; Lee HJ; So JY; Maehr H; Rochel N
J Steroid Biochem Mol Biol; 2017 Oct; 173():69-74. PubMed ID: 27650654
[TBL] [Abstract][Full Text] [Related]
11. Modeling vitamin D actions in triple negative/basal-like breast cancer.
LaPorta E; Welsh J
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():65-73. PubMed ID: 24239860
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
[TBL] [Abstract][Full Text] [Related]
13. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
[TBL] [Abstract][Full Text] [Related]
14. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
18. Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotype.
Laranjo M; Carvalho MJ; Costa T; Alves A; Oliveira RC; Casalta-Lopes J; Cordeiro P; Botas F; Abrantes AM; Paiva A; Oliveira C; Botelho MF
Breast; 2018 Apr; 38():22-29. PubMed ID: 29182983
[TBL] [Abstract][Full Text] [Related]
19. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J
J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210
[TBL] [Abstract][Full Text] [Related]
20. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
Strietz J; Stepputtis SS; Preca BT; Vannier C; Kim MM; Castro DJ; Au Q; Boerries M; Busch H; Aza-Blanc P; Heynen-Genel S; Bronsert P; Kuster B; Stickeler E; Brabletz T; Oshima RG; Maurer J
Oncotarget; 2016 Dec; 7(50):83278-83293. PubMed ID: 27829216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]